PERSISTENT FUNGEMIA WITH CANDIDA AURIS IN A PATIENT WITH ENTEROCUTANEOUS FISTULA

EARLY IDENTIFICATION, PROMPT ANTIFUNGALS, AND ANCILLARY MEASURES ARE KEY TO THERAPY

AUTHORS

- Aveek Mukherjee MDa
- Raisa Ghosh MDa
- Haris Rana MDa

^aDepartment of Internal Medicine, Saint Peter's University Hospital, New Brunswick, NJ.

INTRODUCTION:

 Candida auris is an emerging fearsome adversary in debilitated and ICU patients


CASE:

- 61yo F presented with increased enterocutaneous fistula leakage
- Initial blood cultures negative, urine grew K pneumoniae and Streptococcus
- Deteriorated and shifted to ICU
- 3 more blood cultures negative
- 4th blood culture grew *Candida* duobushaemulonii on VITEK

PRESENTED AT







Candida auris organisms

Source: CDC-PHIL, Stephanie Rossow https://phil.cdc.gov/Details.aspx?pid=23239



Candida auris culture

Source: CDC-PHIL, Shawn Lockhart https://phil.cdc.gov/Details.aspx?pid=21796

CASE (contd.):

- BAL and urine cultures now grew Candida
- Persistent candidemia despite Micafungin, line exchange and line holiday
- *C auris* confirmed by reference laboratory
- New mitral and aortic vegetations
- Deteriorated despite aggressive measures

DISCUSSION:

- Candida auris frequently misidentified on VITEK
- CDC guidelines recommend accurate identification of *C duobushaemulonii*
- Risk factors: surgery, cancer, DM, prolonged ICU stay
- Blood cultures and (1-3)- β -D-glucan assay are specific for diagnosis
- Native and prosthetic valve endocarditis
- Persistence via biofilm
- Azole resistance
- Echinocandins and Amphotericin B for treatment
- Ancillary measures

CLINICAL IMPLICATIONS

- Early identification
- Prompt antifungal therapy
- Foreign body removal
- May need surgery
- Contact precautions
- Strict infection control









SCAN FOR OUR ABSTRACT

